Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Diarrhea 3Rectal Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Medullary 1

Interventions

vandetanib 12cabozantinib 8selpercatinib 5Sorafenib 5Everolimus 5Magnetic Resonance Spectroscopy 3Capecitabine 3sargramostim 2pralsetinib 2lutetium Lu 177 dotatate 2lenvatinib 2Trastuzumab 2Temozolomide 2Sunitinib 2Octreotide 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1veliparib 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1rovalpituzumab tesirine 1ponatinib 1pentetreotide 1pembrolizumab 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Medullary × Calcium Aluminosilicate × Clear all
NCT01739634 2012-12-03

The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer

Salient Pharmaceuticals Incorporated

Phase 1/2 Unknown
10 enrolled

Diarrhea, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡